Skip to main content
Journal cover image

The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass.

Publication ,  Journal Article
Li, JS; Jaggers, J; Anderson, PAW
Published in: Expert Rev Cardiovasc Ther
September 2006

Cardiopulmonary bypass (CPB) for cardiac surgery or lung transplantation initiates a systemic inflammatory response characterized by increased vascular permeability, generalized edema, abnormal lung function and oxygenation and impaired ventricular function. This post-CPB syndrome significantly contributes to postoperative morbidity and mortality. Activation of complement during CPB is a key component that initiates and augments this process. TP10, soluble complement receptor 1, is a novel complement inhibitor that is a potent inhibitor of C3 and C5 convertases, blocking activation of the complement cascade at the nexus of all three complement pathways. Recent controlled trials in humans have demonstrated that TP10 effectively inhibits complement activation during CPB. In high-risk adult patients, TP10 decreases the incidence of mortality and myocardial infarction in males but not in females following cardiac surgery. TP10 is also well tolerated and protects vascular function in infants undergoing CPB. In addition, TP10 leads to early extubation in adult lung transplant recipients. TP10 is currently positioned for clinical development in a male-only indication of cardiac surgery on CPB.

Duke Scholars

Published In

Expert Rev Cardiovasc Ther

DOI

EISSN

1744-8344

Publication Date

September 2006

Volume

4

Issue

5

Start / End Page

649 / 654

Location

England

Related Subject Headings

  • Treatment Outcome
  • Receptors, Complement
  • Lung Transplantation
  • Lung
  • Humans
  • Complement Inactivating Agents
  • Cardiovascular System & Hematology
  • Cardiovascular Diseases
  • Cardiopulmonary Bypass
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, J. S., Jaggers, J., & Anderson, P. A. W. (2006). The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev Cardiovasc Ther, 4(5), 649–654. https://doi.org/10.1586/14779072.4.5.649
Li, Jennifer S., James Jaggers, and Page A. W. Anderson. “The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass.Expert Rev Cardiovasc Ther 4, no. 5 (September 2006): 649–54. https://doi.org/10.1586/14779072.4.5.649.
Li JS, Jaggers J, Anderson PAW. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev Cardiovasc Ther. 2006 Sep;4(5):649–54.
Li, Jennifer S., et al. “The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass.Expert Rev Cardiovasc Ther, vol. 4, no. 5, Sept. 2006, pp. 649–54. Pubmed, doi:10.1586/14779072.4.5.649.
Li JS, Jaggers J, Anderson PAW. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev Cardiovasc Ther. 2006 Sep;4(5):649–654.
Journal cover image

Published In

Expert Rev Cardiovasc Ther

DOI

EISSN

1744-8344

Publication Date

September 2006

Volume

4

Issue

5

Start / End Page

649 / 654

Location

England

Related Subject Headings

  • Treatment Outcome
  • Receptors, Complement
  • Lung Transplantation
  • Lung
  • Humans
  • Complement Inactivating Agents
  • Cardiovascular System & Hematology
  • Cardiovascular Diseases
  • Cardiopulmonary Bypass
  • 3201 Cardiovascular medicine and haematology